The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5098-5103

  Montalvao, Fabricio ^a,b   Garcia, Zacarias ^a,b   Celli, Susanna ^a,b   Breart, Béatrice ^a,b   Deguine, Jacques ^a,b   Rooijen, Nico Van ^c   Bousso, Philippe ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSTITUT PASTEUR   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HUMORAL IMMUNE DEFICIENCY; IMAGING; INTRAVITAL IMAGING; KUPFFER CELL; LIVER; LIVER SINUSOID; LYMPHOID ORGAN; LYMPHOMA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; BURKITT LYMPHOMA; CLODRONIC ACID; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; KUPFFER CELLS; LIPOSOMES; LIVER; LIVER REGENERATION; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OPTICAL IMAGING; PHAGOCYTOSIS;

EID: 84890087376     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70972     Document Type: Article

References (25)

1. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008-2016.
2. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10(5):301-316.
3. Weiner LM, Surana R, Wang S. Monoclonal antibodies:versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317-327.
4. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-446.
5. Uchida J, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti- CD20 antibody immunotherapy. J Exp Med. 2004; 199(12):1659-1669.
6. Cartron G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR3a gene. Blood. 2002;99(3):754-758.
7. Biburger M, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011;35(6):932-944.
8. Boross P, Leusen JH. Mechanisms of action of CD20antibodies. Am J Cancer Res. 2012;2(6):676-690.
9. Sarikonda G, et al. Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS ONE. 2013; 8(2):e54712.
10. Cyster JG, Goodnow CC. Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords. J Exp Med. 1995;182(2):581-586.
11. Ganesan LP, et al. FcgammaR2b on liver sinusoidal endothelium clears small immune complexes.J Immunol. 2012;189(10):4981-4988.
12. Burnett SH, et al. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J Leukoc Biol. 2004;75(4):612-623.
13. MacDonald KP, et al. An antibody against the colony- stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumorassociated macrophages but does not inhibit inflammation. Blood. 2010;116(19):3955-3963.
14. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
15. Gong Q, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174(2):817-826.
16. Nemeth E, Baird AW, O'Farrelly C. Microanatomy of the liver immune system. Semin Immunopathol. 2009;31(3):333-343.
17. van der Bij GJ, et al. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol. 2010;53(4):677-685.
18. de Haij S, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010;70(8):3209-3217.
19. Chao MP, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010; 142(5):699-713
20. Mossner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
21. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-3837.
22. Luche H, Weber O, Nageswara Rao T, Blum C,Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol. 2007;37:43-53.
23. Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 1997;25(6):1317-1318.
24. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1-2):83-93.
25. Celli S, Lemaitre F, Bousso P. Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. Immunity. 2007;27(4):625-634.